A firm touting itself as “Britain’s first psychedelic healthcare fund” has launched with the intention to invest more than £10 million ($13.5 million) in psychedelic focused companies.
Neo Kuma Ventures will fund what it believes are “the most exciting, high quality and scientifically sound players in the industry.” The fund has previously invested in atai Life Sciences, Beckley Psytech, and Brightminds.
The fund’s founders are:
- Clara Burtenshaw, a 35-year old lawyer
- Sean McLintock, a 30-year old entrepreneur who founded a CBD drinks company Drink Three Dots
- Nick David, who will lead Investor Relations
With much of the current investments occurring in the US and Canada, Neo Kuma aims to capitalize on the European psychedelic market.
As cofounder Sean McLintock stated, “As the medical benefits of psychedelics become more well-known and regulators steadily increase their embrace of these types of drugs, the industry is set for a boom. While much of the conversation on psychedelics is taking place in the US, Europe is the true hub of the burgeoning psychedelic healthcare sector.”
Psychedelic Invest has reached out to Neo Kuma to gather more information on the fund and the founders backgrounds & thesis.